Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 25 or more amino acid residues in defined sequence
Reexamination Certificate
2007-03-09
2010-02-23
Huff, Sheela J (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
25 or more amino acid residues in defined sequence
C530S326000
Reexamination Certificate
active
07666983
ABSTRACT:
The present invention provides peptides and peptidomimetics corresponding to part or to the entirety of the region encompassed by residues 360-386 of human p53, said peptides and peptidomimetics characterized by the ability to activate DNA binding of wild-type p53 and of select tumor-derived p53 mutants. Pharmaceutical compositions of the compounds of the invention and methods of using these compositions therapeutically are also provided.
REFERENCES:
patent: 6169073 (2001-01-01), Halazonetis et al.
patent: 6245886 (2001-06-01), Halazonetis et al.
patent: 6420118 (2002-07-01), Halazonetis et al.
patent: 0518650 (1992-12-01), None
patent: 94/08241 (1994-04-01), None
patent: 94/10306 (1994-05-01), None
patent: 94/12202 (1994-06-01), None
patent: 95/17213 (1995-06-01), None
Brady et al., “Reflections on a Peptide,” Nature, 368:692 693 (1994).
Bugg et al., “Drugs by Design,” Sci. Am., 269:92 98 (1993).
Cho et al., “Crystal Structure of a p53 Tumor Suppressor DNA Complex: Understanding Tumorigenic Mutations,” Science, 265:346 355 (1994).
Clore et al., “High Resolution Structure of the Oligomerization Domain of p53 by Multidimensional NMR,” Science, 265:386 391 (1994).
Coller et al., “Substituting Isoserine for Serine in the Thrombin Receptor Activation Peptide SFLLRN Confers Resistance to Aminopeptidase M induced Cleavage and Inactivation,” J. Biol. Chem, 268(28):20741 20743 (1993).
Couder, J. et al. “Synthesis and biological activities of u(CH2NH) pseudopeptide analogues of the C-terminal hexapeptide of neurotensin” Int. J. Peptide Protein Res. vol. 41, No. 2, p. 181-184.
Cox et al., “Xenopus p53 is Biochemically Similar to the Human Tumour Suppressor Protein p53 and is Induced upon DNA Damage in Somatic Cells,” Oncogene, 9:2951 2959 (1994).
Dean, “Recent Advances in Drug Design Methods” Where Will They Lead? BioEssays, 16:683 687 (1994).
Delpozzo, A. et al. “H-Gly-Hisu(NHCO(Lys-OH, partially modified retro-inverso analogue of the growth factor glycyl-L-histidyl-L-lysine with enhancedenzymatic stability” Int. J. Peptide Protein Res. vol. 41, p. 561-566.
Finlay et al., “The p53 Proto Oncogene Can Act as a Suppressor of Transformation,” Cell , 57:1083 1093 (1989).
Friend, “p53: A Glimpse at the Puppet Behind the Shadow Play,” Science, 265:334 335 (1994).
Fujiwara et al., “A Retroviral Wild Type p53 Expression Vector Penetrates Human Lung Cancer Spheroids and Inhibits Growth by Inducing Apoptosis,” Cancer Res., 53:4129 4133 (1993).
Halazonetis et al., “Conformational Shifts Propagate from the Oligomerization Domain of p53 to its Tetrameric DNA Finding Domain and Restore DNA Binding to Select p53 Mutants,” EMBO J., 12:5057 5064 (1993).
Halazonetis et al., “Wild Type p53 Adopts a ‘Mutant’ like Conformation when Bound to DNA,” EMBO J., 12:1021 1028 (1993).
Hruby, “Conformational and Topographical Consideration in the Design of Biologically Active Peptides,” Biopolymers, 33:1073 1082 (1993).
Hupp et al., “Regulation of the Cryptic Sequence Specific DNA Binding Function of p53 by Protein Kinases,” Cold Spring Harbor Symposia on Quantitative Biology, vol. LIX, pp. 195 205 (1994).
Hupp et al, “Small Peptides Activate the Latent Sequence Specific DNA Binding Function of p53,” Cell, 83:237 245 (1995).
Hupp et al., “Regulation of the Specific DNA Binding Function of p53,” Cell, 71:857 886 (1992).
Hupp et al., “Activation of the Cryptic DNA Binding Function of Mutant Forms of p53,” Nucleic Acids Res., 21:3167 3174 (1993).
Hupp, et al. “Allosteric activation of latent p53 tetramers” Current Biology, vol. 4, No. 10, p. 865-875.
Jameson et al., “A Rationally Designed CD4 Analogue Inhibits Experimental Allergic Encephalomyelitis,” Nature, 368 744 746 (1994).
Moore, “Designing Peptide Mimetics,” Trends Pharmacol. Sci., 15:124 129 (1994).
Naoko Arai et al. “Immunologically Distinct p53 Molecules Generated by Alternative Splicing,” Molecular and Cellular Biology, vol. 6, No. 9, Sep. 1986, p. 3232-3239.
Powell, et al. “Peptide Stabiliyt in drug development. II. Effect of single amino acid substitution and glycosylation onp eptide reactivity in human serum” Pharmaceutical Research, vol. 10, No. 9, 1993.
Shaw et al., “Regulation of Specific DNA Binding by p53: Evidence for a Role of o Glycosylation and Charged Residues at the Carboxy terminus,” Oncogene, 12:921 930 (1996).
Soussi et al., “Structural Aspects of the p53 Protein in Relation to Gene Evolution,” Oncogene, 5:945 952 (1990).
Speir et al., “Potential Role of Human Cytomegalovirus and p53 Interaction in Coronary Restenosis,” Science, 265:391 394 (1994).
Stryer, Biochemistry second edition, p. 13-17, 1981.
Takenaka et al., “Regulation of the Sequence Specific DNA Binding Function of p53 by Protein Kinase C and Protein Phosphatases,” J. Biol. Chem., 270(10):5405 5411 (1995).
Tanigaki et al.,Immunogenetics, vol. 40, p. 192, 1994.
Wade Evans et al., “Precise Epitope Mapping of the Murine Transformation Associated Protein, p53,” EMBO J., 4″699 706 (1985).
Halazonetis Thanos
Hartwig Wolfgang
Banner & Witcoff , Ltd.
Bayer Healthcare LLC
Huff Sheela J
The Wistar Institute
LandOfFree
Peptides and peptidomimetics with structural similarity to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptides and peptidomimetics with structural similarity to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides and peptidomimetics with structural similarity to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4153591